Topic 1

sars cov covid 19 coronavirus pandemic virus viral spike respiratory infection ace2 severe 2019 syndrome acute vaccine receptor entry host antiviral against coronaviruses microbiology viruses disease rbd infected antibodies vaccines caused replication binding human neutralizing outbreak angiotensin spread antibody protein converting global patients health immunology glycoprotein domain lung clinical worldwide public china immune infections enzyme rna effective drug therapeutic epitopes transmission wuhan 2020 mers drugs protease therapeutics potent potential has world ongoing neutralization tmprss2 approved rapid infectious rapidly s1 urgent deaths design epitope nucleocapsid ncov pathogenesis agent december currently assay cov2 convalescent novel target development structural cases anti treatment infectivity

2069 items. Top items listed below.

Many bat species are not potential hosts of SARS-CoV and SARS-CoV-2: Evidence from ACE2 receptor usage 36 1

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement 36 24 1

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2 36 1

Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 36 1

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies 36 24 1

Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations. 36 1

SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry 36 1

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability 36 24 1

Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin Converting Enzyme 2 Receptor 36 1

Potential microenvironment of SARS-CoV-2 infection in airway epithelial cells revealed by Human Protein Atlas database analysis 36 1

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines against COVID-19 24 1

Interaction of human ACE2 to membrane-bound SARS-CoV-1 and SARS-CoV-2 S glycoproteins 36 1

TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets 44 1

De novo design of ACE2 protein decoys to neutralize SARS-CoV-2 36 1

Computational analysis on the ACE2-derived peptides for neutralizing the ACE2 binding to the spike protein of SARS-CoV-2 36 1

Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. 36 1

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike 24 1

Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction 36 1

SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients 24 1

The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity 36 1

Which animals are at risk? Predicting species susceptibility to Covid-19 36 1

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies 76 1

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections 24 1

Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2 36 1

Increasing Host Cellular Receptor--Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection 36 1

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling 36 1

Spike protein binding prediction with neutralizing antibodies of SARS-CoV-2 1

Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1 36 1

CD8+ T cell cross-reactivity against SARS-CoV-2 conferred by other coronavirus strains and influenza virus 191 76 1

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection 36 1

Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis 36 24 1

SARS-CoV-2 mutations and where to find them: An in silico perspective of structural changes and antigenicity of the Spike protein 103 1

Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men 36 1

Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide 73 36 1

Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction. 36 1

The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection 36 1

Insights on cross-species transmission of SARS-CoV-2 from structural modeling 103 1

Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2. 36 1

Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza 103 1

Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes 24 1

The immunodominant and neutralization linear epitopes for SARS-CoV-2 24 1

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells 103 36 1

A simple protein-based surrogate neutralization assay for SARS-CoV-2 36 24 1

SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins 36 1

Identification of TMEM106B as proviral host factor for SARS-CoV-2 73 1

High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples 24 1

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples 130 24 1

Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis 103 1

Elucidating the differences in the molecular mechanism of receptor binding between 2019-nCoV and the SARS-CoV viruses using computational tools 36 1

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 24 1

Shotgun proteomics of SARS-CoV-2 infected cells and its application to the optimisation of whole viral particle antigen production for vaccines 103 1

Strong evolutionary convergence of receptor-binding protein spike between COVID-19 and SARS-related coronaviruses 36 1

Cyclooxgenase-2 is induced by SARS-CoV-2 infection but does not affect viral entry or replication 36 1

Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry 36 1

Targeted Intracellular Degradation of SARS-CoV-2 RBD via Computationally-Optimized Peptide Fusions 1

A human monoclonal 1 antibody blocking SARS-CoV-2 infection 1

Detection of Viral RNA Fragments in Human iPSC-Cardiomyocytes following Treatment with Extracellular Vesicles from SARS-CoV-2 Coding-Sequence-Overexpressing Lung Epithelial Cells 36 1

When Darkness Becomes a Ray of Light in the Dark Times: Understanding the COVID-19 via the Comparative Analysis of the Dark Proteomes of SARS-CoV-2, Human SARS and Bat SARS-Like Coronaviruses 103 1

Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein 36 1

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity 44 1

Oral epithelial expression of angiotensin converting enzyme-2: Implications for COVID-19 diagnosis and prognosis. 36 1

Re-analysis of SARS-CoV-2 infected host cell proteomics time-course data by impact pathway analysis and network analysis. A potential link with inflammatory response. 73 1

Molecular mechanism of evolution and human infection with the novel coronavirus (2019-nCoV) 36 1

Development of a fluorescence based, high-throughput SARS-CoV-2 3CLpro reporter assay 44 1

Host range projection of SARS-CoV-2: South Asia perspective 36 1

mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2 191 36 24 1

Virus-free and live-cell visualizing SARS-CoV-2 cell entry for studies of neutralizing antibodies and compound inhibitors 36 1

Preclinical study of DNA vaccines targeting SARS-CoV-2 24 1

SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus 73 1

Distinct Structural Flexibility within SARS-CoV-2 Spike Protein Reveals Potential Therapeutic Targets 103 1

Towards the design of multiepitope-based peptide vaccine candidate against SARS-CoV-2 191 76 36 1

Structural basis for the recognition of the 2019-nCoV by human ACE2 36 1

SARS-CoV-2 Nucleocapsid protein is decorated with multiple N- and O-glycans. 103 1

Potent mouse monoclonal antibodies that block SARS-CoV-2 infection 103 1

FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells 44 1

Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques 73 1

Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2 44 1

SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation 130 103 1

Hypertonic saline solution inhibits SARS-CoV-2 in vitro assay 36 1

Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro 44 1

Interferons and viruses induce a novel primate-specific isoform dACE2 and not the SARS-CoV-2 receptor ACE2 36 1

Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice 24 1

SARS-CoV-2 infection severity is linked to superior humoral immunity against the spike 24 1

Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein 24 1

Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection 24 1

Antiviral effects of miRNAs in extracellular vesicles against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mutations in SARS-CoV-2 RNA virus 73 1

Comparative transcriptome analysis reveals the intensive early-stage responses of host cells to SARS-CoV-2 infection 73 1

Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection 103 44 1

SARS-CoV-2 protein subunit vaccination elicits potent neutralizing antibody responses 24 1

Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility 24 1

Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins 24 1

Designing of Epitope-Based Vaccine from the Conserved Region of the Spike Glycoprotein of SARS-CoV-2 191 76 24 1

SARS-CoV-2 Isolation and Propagation from Turkish COVID-19 patients 103 1

Transferrin receptor is another receptor for SARS-CoV-2 entry 36 1

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody 24 1

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. 44 1

Characterization of the SARS-CoV-2 Spike in an Early Prefusion Conformation 103 1

High-Throughput Human Primary Cell-Based Airway Model for Evaluating Influenza, Coronavirus, or other Respiratory Viruses in vitro 1

Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19 73 1

Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases 44 1